Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Setbacks, Emphysema Devices Find Funding

Executive Summary

Minimally invasive emphysema devices have seen their ups and downs over the years, but despite technological and regulatory challenges, VCs continue to fund these devices, with investments driven by the market opportunity, huge unmet clinical need, and promising technologies.

Advertisement

Related Content

U.S. Approval, Sales Milestones Could Double PneumRx Price For BTG
U.S. Approval, Sales Milestones Could Double PneumRx Price For BTG
Breathe Technologies: Penetrating The Ventilator Market
Medical Device Market & Industry Briefs, April 2012
Waiting For Exhale: Emphysema Researchers Call For New Stent Designs, More Analysis
Pulmonary Device Companies Take It To The Streets - In Europe
Asthmatx Acquisition By Boston Scientific Is Source of Many Happy Returns
Emphysema Devices Search for Breathing Room
Emphasys On The Block After FDA Panel Rejection Of Pulmonary Valve

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT035501

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel